Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke.
نویسندگان
چکیده
Two patients with acute major, disabling cerebral infarction with presumed middle cerebral artery occlusion were treated with the clot specific thrombolytic agent tissue plasminogen activator roughly three and a half hours after the onset of symptoms. Both patients had a normal computed tomography (CT) scan before treatment. No appreciable systemic bleeding complications occurred, apart from bruising. One patient had bleeding into the subarachnoid space from a microscopic angioma, which was found at necropsy. Haematological monitoring of the two patients showed pronounced fibrinogenolysis and alpha 2 antiplasmin consumption in one. One patient showed transient improvement during the infusion. In both cases extensive infarction, partly haemorrhagic in one, with massive concomitant oedema was found on repeated CT. Both patients deteriorated and eventually died as a consequence of transtentorial herniation. In the one patient who came to necropsy a moderate, probably pre-existing smooth stenosis of the ipsilateral carotid artery was found, all cerebral vessels being patent. It is concluded that thrombolytic treatment with a clot specific agent such as tissue plasminogen activator started three to four hours after a major ischaemic stroke may be hazardous, not because of haemorrhagic transformation of the original ischaemia but because early reperfusion may promote massive, potentially fatal cerebral oedema.
منابع مشابه
Intravenous Thrombolysis for Acute Ischemic Stroke due to Cardiac Myxoma; A Case Report
Myxoma may cause systemic embolization and frequently presents as ischemic stroke. There has been debates whether it is safe to use recombinant tissue plasminogen activator (rt-PA) in patients with cardiac myxoma who are presented with ischemic stroke at emergency department. we describe a young case of atrial myxoma with initial presentation of acute cerebral infarction symptoms who was treate...
متن کاملSafety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke
Background: Thrombolytic therapy is the only approved treatment for acute cerebral ischemia. The hemorrhagic transformation is the greatest complication of this treatment, which may occur after recanalization of occluded artery. The aim of this study was to determine factors associated with clinical improvement and worsening in patients with acute ischemic stroke treated with intravenous th...
متن کاملThrombolysis in Stroke Patients; Problems and Limitations
Thrombolysis for stroke is being used in some developing countries. This study was designed to evaluate the problems of thrombolysis therapy in Iran. During January-July 2008, all patients with ischemic stroke admitted to Ghaem Hospital, Mashhad, northeast Iran, were enrolled in a prospective observational study. Ghaem Hospital is a tertiary care hospital that includes infrastructure for thromb...
متن کاملReducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising Minocycline
Haemorrhagic transformation (HT) of recently ischaemic brain is a feared complication of thrombolytic therapy that may be caused or compounded by ischaemia-induced activation of matrix metalloproteinases (MMPs). The tetracycline antibiotic minocycline inhibits matrix MMPs and reduces macroscopic HT in rodents with stroke treated with tissue plasminogen activator (tPA). The West Australian Intra...
متن کاملA case of acute myocardial infarction 24 hours after acute ischaemic stroke.
Dear Editor, It is well known that thrombolysis for acute myocardial infarction (AMI) may lead to disintegration of pre-existing intracardiac thrombi with subsequent cerebral embolisation. It appears plausible that the same mechanism could apply to patients with cardiac or arterial thrombi who are undergoing intravenous thrombolysis for acute ischaemic stroke. AMI immediately following tissue p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- BMJ
دوره 297 6663 شماره
صفحات -
تاریخ انتشار 1988